Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

F. Salomone,I. Cacciola,S. Petta,V. Calvaruso,A. Micek,S. Madonia, M. Grova,M. Distefano, M. Cannavò, M.A. Di Rosolini,A. Digiacomo,F. Di Lorenzo,G. Bertino,A. Licata, F. Latteri,F. Benanti,A. Averna,L. Guarneri,I. Scalisi,C. Iacobello

Digestive and Liver Disease（2022）

引用 0|浏览35

暂无评分

摘要

Background and aims: Real-world data on the efficacy and safety of pangenotypic direct antiviral agents (DAAs) for chronic HCV infection are limited. In this study we assessed the efficacy and safety of sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) in the RESIST-HCV cohort.

查看译文

关键词

chronic hcv infection,pangenotypic daas,real-world,resist-hcv

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要